

## REMARKS

Claims 4 and 38 are currently amended. Claims 58-63 are canceled. Claims 76-82 are new. No new matter is added.

### **I. The rejection of Claims 22, 23, 58-63 under 35 U.S.C. 112, 1st (Written description)**

Claim 4 is currently amended. Accordingly, claims 22 and 23 which depend upon claim 4 are narrowed and meet the written description requirement. Reconsideration is urged. The remaining claims 58-63 are canceled. Accordingly, any rejection to claims 58-63 is moot.

### **II. The rejection of Claims 4, 21-26, 58, 61-63 under 35 U.S.C. 112, 2nd**

Claim 4 is currently amended. Reconsideration is urged.

In light of the amendment to claim 4, Claims 21-26 are clear. Reconsideration is urged.

Claims 58-63 are canceled. Accordingly any rejection of these claims is moot.

### **III. The rejection of claims 4, 21-26, 38, 40-48 under 35 U.S.C. 102(b)**

Claims 4, 21-26, 38, 40-48 are rejected under 35 U.S.C. 102(b) as being anticipated by Martzen et al. (Science, 286, no. 5442:1153-1155, 1999) hereinafter referred to simply as "Martzen").

Independent claims 4 and 38 require, *inter alia*, a gene encoding peptide disulphide isomerase (PDI), and a first recombinant gene encoding a protein comprising the sequence of protein disulphide isomerase (PDI), respectively. Nowhere does Martzen mention PDI. In Martin, only 6144 of the 6607 *S. cerevisiae* proteins were expressed as GST fusions – therefore PDI was not explicitly expressed as a GST fusion. Reconsideration is urged.

### **IV. The rejection of claims 38, 40, 43-46 under 35 U.S.C. 102(e)**

Claims 38, 40, 43-46 stand rejected under 35 U.S.C. 102(e) as being anticipated by Conneely (U.S. Patent No. 5,571,691).

Claim 38 is currently amended. Reconsideration is urged.

### **V. New Claims**

Claims 76-82 are added to reflect Claims 41, 42, 47 and 48 being allowable. Consideration of these claims is urged. No new matter is added. Should any additional

fees be due the USPTO is authorized to charge the deposit Account of Novozymes North America, Inc. Deposit Account No. 50-1701.

**VI. Conclusion**

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application. Should any additional fees be due the USPTO is authorized to charge the deposit account of Novozymes North America, Inc. *i.e.*, Deposit Account No. 50-1701.

Date: August 12, 2010

Respectfully submitted,

/Michael W. Krenicky Reg#45411/  
Michael W. Krenicky, Reg. No. 45,411  
Novozymes North America, Inc.  
500 Fifth Avenue, Suite 1600  
New York, NY 10110  
(212) 840-0097